Tempus AI surges 12.5% on new AI tools, a $200M AstraZeneca deal, and clinical data expansion- but is it time to buy?

IonQ (IONQ) announced results of a research program between the company, AstraZeneca (AZN), Amazon Web Services (AMZN) and Nvidia (NVDA).

TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEM’s main bet is now on AI for ...

NEW YORK, June 7, 2025 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM). Such investors are advised to contact ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Tempus AI TEM is currently in its 10th year of business and on track to hit a long-anticipated milestone. In its first-quarter 2025 earnings report, the AI-driven healthcare company guided full-year ...

How AI is reshaping biotech through partnerships, from drug discovery to clinical trials, and what it means for the future of ...